"The voice of oncology in Massachusetts."

FDA approves ibrutinib (IMBRUVICA) plus rituximab for chronic lymphocytic leukemia

April 23, 2020 10:50 AM | Anonymous

The U.S. Food and Drug Administration expanded the indication of ibrutinib (IMBRUVICA, Pharmacyclics LLC) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read full press release

Massachusetts Society of Clinical Oncologists ©2023

860 Winter Street, Waltham, MA, 02451
Tel: 781.434.7329  |  email: msco@mms.org

Powered by Wild Apricot Membership Software